Sign up to save your podcasts
Or
Share Challenging Cases with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Challenging Cases with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Welcome to this episode of The Oncology Brothers! Drs. Rahul and Rohit Gosain dived into the complexities of relapsed refractory diffuse large B-cell lymphoma (DLBCL) with their new series focused on challenging real-life cases.
In this episode, we are joined by esteemed guests Dr. Carla Casulo from Wilmot Cancer Center and Dr. Tara Graff from Mission Cancer and Blood Center. Together, we explored the current standard of care, including R-CHOP and the role of bi-specific antibodies like epcoritamab and glofitimab.
Key topics covered included:
• When to use bi-specific antibodies and how to manage side effects
• The importance of MRD monitoring in treatment decisions
• Insights on patient management in community oncology settings
• The evolving landscape of treatment options for DLBCL, including CAR-T therapy and clinical trials
We also discuss practical considerations for community oncologists, including the management of cytokine release syndrome (CRS) and the role of immunoglobulin therapy in patients with low IgG levels.
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions.
YouTube: https://youtu.be/05ieIyAIx_8
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and share your thoughts in the comments! Let us know if there are specific scenarios you'd like us to cover in future episodes.
View all episodes
By Oncology Brothers
4.8
3939 ratings
Welcome to this episode of The Oncology Brothers! Drs. Rahul and Rohit Gosain dived into the complexities of relapsed refractory diffuse large B-cell lymphoma (DLBCL) with their new series focused on challenging real-life cases.
In this episode, we are joined by esteemed guests Dr. Carla Casulo from Wilmot Cancer Center and Dr. Tara Graff from Mission Cancer and Blood Center. Together, we explored the current standard of care, including R-CHOP and the role of bi-specific antibodies like epcoritamab and glofitimab.
Key topics covered included:
• When to use bi-specific antibodies and how to manage side effects
• The importance of MRD monitoring in treatment decisions
• Insights on patient management in community oncology settings
• The evolving landscape of treatment options for DLBCL, including CAR-T therapy and clinical trials
We also discuss practical considerations for community oncologists, including the management of cytokine release syndrome (CRS) and the role of immunoglobulin therapy in patients with low IgG levels.
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions.
YouTube: https://youtu.be/05ieIyAIx_8
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and share your thoughts in the comments! Let us know if there are specific scenarios you'd like us to cover in future episodes.
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
320 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
Research To Practice | Oncology Videos
111 Listeners
JAMA Clinical Reviews
501 Listeners
ASCO Daily News
60 Listeners
Core IM | Internal Medicine Podcast
1,110 Listeners
OncoPharm
182 Listeners
ASCO Guidelines
46 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
350 Listeners
Lung Cancer Considered
27 Listeners
The Passive Income MD Podcast
277 Listeners
Oncology Today with Dr Neil Love
60 Listeners
Two Onc Docs
181 Listeners
Blood Cancer Talks
48 Listeners